{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["60(6)"],"submitter":["Mendes RE"],"pubmed_abstract":["Oritavancin (MIC50/90, 0.03/0.06 to 0.12 μg/ml) had potent activity against linezolid-resistant staphylococci, as well as Enterococcus faecalis and Enterococcus faecium (oritavancin MIC50/90, 0.015/0.12 μg/ml against both species). All linezolid-resistant isolates were inhibited by oritavancin at ≤0.12 μg/ml. These results confirmed the absence of cross-resistance between linezolid and oritavancin in staphylococci and enterococci."],"journal":["Antimicrobial agents and chemotherapy"],"pagination":["3817-20"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4879412"],"repository":["biostudies-literature"],"pubmed_title":["Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results."],"pmcid":["PMC4879412"],"pubmed_authors":["Farrell DJ","Mendes RE","Flamm RK","Jones RN","Sader HS"],"additional_accession":[]},"is_claimable":false,"name":"Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results.","description":"Oritavancin (MIC50/90, 0.03/0.06 to 0.12 μg/ml) had potent activity against linezolid-resistant staphylococci, as well as Enterococcus faecalis and Enterococcus faecium (oritavancin MIC50/90, 0.015/0.12 μg/ml against both species). All linezolid-resistant isolates were inhibited by oritavancin at ≤0.12 μg/ml. These results confirmed the absence of cross-resistance between linezolid and oritavancin in staphylococci and enterococci.","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Jun","modification":"2025-04-05T14:58:53.734Z","creation":"2025-04-05T14:58:53.734Z"},"accession":"S-EPMC4879412","cross_references":{"pubmed":["27001823"],"doi":["10.1128/aac.00281-16","10.1128/AAC.00281-16"]}}